What is the pathophysiology of hepatitis?

Pathophysiology of Hepatitis

Core Mechanism: Non-Cytopathic Viral Infection with Immune-Mediated Damage

Hepatitis B and C viruses are non-cytopathic, meaning liver damage results primarily from the host immune response attempting to clear infected hepatocytes, not from direct viral cytotoxicity 1, 2, 3. This fundamental principle explains why chronic infection persists and why progressive liver disease develops.

Hepatitis B Virus (HBV) Pathophysiology

Viral Replication and Persistence

HBV replicates through reverse transcription within hepatocytes, producing:

• Covalently closed circular DNA (cccDNA): The episomal template that persists in the nucleus and drives ongoing viral transcription 1
• Integrated HBV DNA: Linear DNA randomly inserts into host chromosomes in ~10% of replication events, accumulating over time and promoting hepatocellular carcinoma (HCC) through gene disruption, chromosomal translocations, and HBx protein expression 1

Immune-Mediated Injury

The pathogenic cascade operates as follows:

1. T cell-mediated hepatocyte killing: CD4+ and CD8+ cytotoxic T lymphocytes recognize HBV antigens expressed on infected hepatocytes and destroy them 1, 2
2. Persistent inflammation: Continuous low-level immune activation occurs because the T cell response is inefficient—strong enough to cause damage but too weak to clear the virus 3
3. Progressive fibrosis: Chronic inflammation triggers hepatic stellate cell activation, leading to fibrosis and eventually cirrhosis 4
4. HCC development: Both the mutagenic inflammatory environment and accumulated HBV DNA integrants promote malignant transformation 1

Disease Phase Dynamics

Chronic HBV infection progresses through phases characterized by varying levels of viral replication, immune activity, and liver inflammation 1. The traditional "immune-tolerant" phase (now termed HBeAg-positive chronic infection) features high viral loads with minimal inflammation. Immune activation leads to the HBeAg-positive chronic hepatitis phase with elevated liver enzymes and active damage. The HBeAg-negative phases may show apparent quiescence, but viral escape can trigger aggressive HBeAg-negative chronic hepatitis with accelerated progression to cirrhosis and HCC 1.

Hepatitis C Virus (HCV) Pathophysiology

Immune Evasion and Chronicity

HCV, a single-stranded RNA virus, establishes chronic infection in 60-80% of cases by evading both innate and adaptive immune surveillance 5. Chronic infection results from weak, ineffective CD4+ and CD8+ T cell responses during acute infection that fail to control viral replication 4.

Liver Injury Mechanisms

• Non-specific immune responses: Once chronicity is established, locally driven inflammatory responses—predominantly non-specific rather than targeted—cause ongoing hepatocyte damage 4
• Antigen-nonspecific inflammatory cells: These cells exacerbate cytotoxic T lymphocyte-induced immunopathology 3
• Fibrogenesis: Local inflammation activates hepatic stellate cells, the primary drivers of fibrosis progression 4

Progression to Cirrhosis and HCC

External factors accelerate disease progression:

• Chronic alcohol consumption
• Viral coinfections (HBV, HDV, HIV)
• Age, gender, and race 5, 4

HCC development occurs almost exclusively in patients with established cirrhosis, though the specific role of HCV proteins in hepatocarcinogenesis remains unclear 5, 4.

Hepatitis D Virus (HDV) Coinfection

HDV requires HBsAg for infection and egress, making it obligately dependent on HBV 6. HBV/HDV coinfection represents the most severe form of chronic viral hepatitis, with accelerated progression to cirrhosis and HCC due to enhanced interaction between the two viruses 6.

Common Pathogenic Pathway

Across all chronic viral hepatitis:

1. Ineffective adaptive immune responses fail to clear infection
2. Persistent low-level immune-mediated hepatocyte destruction continues
3. Recurrent cycles of inflammation drive progressive fibrosis
4. Cirrhosis develops over years to decades
5. Cirrhotic livers face high risk of decompensation and HCC 2, 3

Clinical Implications

The non-cytopathic nature of these viruses means that antiviral suppression—by reducing viral antigen expression and new hepatocyte infections—decreases immune-mediated inflammation, slows fibrosis progression, and reduces HCC risk 1. This mechanistic understanding supports earlier treatment initiation, as nucleos(t)ide analogs for HBV limit new hepatocyte infections, reduce cccDNA pools over time, decrease HBV DNA integrations, and diminish pathogenic inflammation 1.